To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this lecture from This is Why, Dr. Busti will teach you about Alpha-Glucosidase Inhibitors for Diabetes — the pharmacology made easy breakdown of acarbose and miglitol for type 2 diabetes.
You’ll learn how to:
- Explain how alpha-glucosidase inhibitors reduce postprandial hyperglycemia
- Identify where these drugs work (GI tract) and why they don’t cause hypoglycemia by themselves
- Compare acarbose vs miglitol (what’s similar, what’s different)
- Recognize common GI adverse effects (e.g., flatulence, diarrhea, abdominal discomfort)
- Know when they are (and are not) used in type 2 diabetes medications
- Apply patient counseling: timing with meals + what to do if hypoglycemia occurs on combination therapy
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00 Intro: Alpha-Glucosidase Inhibitors (Anti-Diabetic Drugs)
01:09 What We’ll Cover: Agents, Uses, Mechanism, Side Effects, Pearls
01:42 Key Agents: Acarbose vs Miglitol
02:19 Indications: Type 2 Diabetes + Post-Bypass Hypoglycemia (Acarbose)
03:04 Net Benefit: Weight Neutral + Low Hypoglycemia Risk + Modest A1C Drop
03:58 Why They’re Rarely Used: GI Side Effects Limit Use
04:46 Mechanism: Inhibits Intestinal Enzyme → Delays Carbohydrate Breakdown
05:34 Hypoglycemia Pearl: Use Glucose/Dextrose (Not Sucrose/Complex Carbs)
06:41 Where They Fit in T2DM Strategy: Lifestyle First, Then Add-On Therapy
09:44 Context: Secretagogues vs Non-Secretagogues (Big Picture Comparison)
12:32 Comorbidities: When to Avoid (IBS/IBD/Obstruction Risk)
14:48 Dosing & Counseling: Titrate Slowly, Take with First Bite, Monitor
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#alphaglucosidaseinhibitors #acarbose #miglitol #type2diabetespharmacology #busti
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
